Africa Pharmaceutical Market Report

Africa Pharmaceutical Market Size

The Africa Pharmaceutical Market is anticipated to rise from USD 27.43 billion in 2024 to USD 38.24 billion in 2033, growing at a CAGR of 3.76%.

Pharmaceutical covers a wide range of products including generic medicines, vaccines, over-the-counter drugs, and specialty pharmaceuticals tailored for both communicable and non-communicable diseases.

According to the African Union, nearly 60% of medicines consumed in Africa are imported, primarily from India and China, due to limited domestic manufacturing capacity and high production costs.

Despite these challenges, there has been a notable shift toward local drug production and regulatory harmonization across regional blocs such as the East African Community and the Economic Community of West African States.

Apart from these, the rise of digital health platforms and improved distribution networks is helping bridge gaps in medicine availability, especially in rural areas. These developments are shaping the trajectory of the Africa pharmaceutical market into a more self-reliant and patient-centered ecosystem.

MARKET DRIVERS

Rising Prevalence of Chronic and Infectious Diseases

The increasing prevalence of both chronic and infectious diseases, which has significantly elevated the demand for medical treatments, is one of the primary drivers of the Africa pharmaceutical market. Non-communicable diseases such as diabetes, hypertension, and cancer are on the rise due to changing lifestyle patterns, urbanization, and aging populations. According to the World Health Organization, in 2023, NCDs accounted for nearly 37% of all deaths in sub-Saharan Africa, up from 28% a decade earlier.

Simultaneously, infectious diseases like malaria, tuberculosis, and HIV/AIDS continue to pose significant public health challenges. As per UNAIDS, in 2023, an estimated 25.6 million people in sub-Saharan Africa were living with HIV, requiring continuous antiretroviral therapy.

These dual burdens have intensified the need for both preventive and curative pharmaceutical products. Governments and global health organizations are responding with expanded treatment programs, vaccination drives, and increased procurement of essential medicines. This sustained demand is driving investment in pharmaceutical production and distribution, fueling growth in the Africa pharmaceutical market.

MARKET RESTRAINTS

Expansion of Healthcare Infrastructure and Insurance Coverage

The expansion of healthcare infrastructure and the gradual increase in health insurance coverage across several countries is another key driver of the Africa pharmaceutical market. As governments invest in building new hospitals, clinics, and diagnostic centers, access to medical services—and consequently, pharmaceutical products—has improved significantly.

According to the African Development Bank, between 2018 and 2023, public health expenditure in sub-Saharan Africa grew at an average annual rate of 6%, with several nations introducing or expanding national health insurance schemes.

In Nigeria, the Federal Ministry of Health launched a renewed push for universal health coverage in 2022, aiming to enroll 50% of the population by 2025.

Improved healthcare access has led to higher diagnosis rates and medication adherence, directly boosting pharmaceutical sales. Besides, private health insurance penetration is rising in urban centers, further stimulating demand for branded and generic medicines. These infrastructural and policy-driven advancements are reinforcing the growth momentum of the Africa pharmaceutical market.

Weak Regulatory Frameworks and Quality Control Issues

The inconsistency and inefficiency of regulatory frameworks across the continent, which undermines drug quality control and market integrity is a major restraint facing the Africa pharmaceutical market. Many African countries lack robust regulatory bodies capable of enforcing stringent approval processes, monitoring counterfeit medicines, and ensuring compliance with international standards.

According to the World Health Organization, in 2023, an estimated 19% of medicines circulating in sub-Saharan Africa were either substandard or falsified, posing serious risks to public health and eroding consumer confidence in locally available drugs. In some markets, weak enforcement mechanisms allow unlicensed manufacturers and distributors to operate with minimal oversight.

Meanwhile, national regulatory authorities often face funding shortages and staffing deficits, hampering their ability to conduct timely product approvals and inspections.

This fragmented regulatory landscape discourages foreign investment and delays the introduction of innovative medicines, ultimately stifling the growth potential of the Africa pharmaceutical market.

High Cost of Local Drug Production and Limited Financing

The high cost of local drug production, which limits competitiveness and discourages investment is another critical constraint in the Africa pharmaceutical market. Domestic manufacturers face numerous challenges, including expensive raw material imports, unreliable energy supply, inadequate transportation infrastructure, and limited access to affordable financing.

According to the United Nations Industrial Development Organization (UNIDO), in 2023, African pharmaceutical producers incurred production costs that were on average 30–50% higher than those of their Asian counterparts, largely due to inefficient supply chains and outdated manufacturing equipment.

Access to capital also remains a major obstacle. As per a report by the African Development Bank, less than 10% of pharmaceutical firms in sub-Saharan Africa had access to long-term financing, making it difficult to scale operations or adopt advanced production technologies. Banks and financial institutions often perceive the sector as high-risk due to inconsistent returns and regulatory uncertainties.

Consequently, many local manufacturers struggle to compete with low-cost imports, particularly from India and China, which dominate the region's drug supply.

MARKET OPPORTUNITIES

Growth of Biopharmaceutical and Vaccine Manufacturing Capabilities

The growing development of biopharmaceutical and vaccine manufacturing capabilities, supported by international partnerships and regional initiatives aimed at strengthening health security, is a major opportunity emerging in the Africa pharmaceutical market. Historically dependent on imports for vaccines and complex biological medicines, several African countries are now investing in local production facilities to ensure faster and more reliable access to life-saving treatments.

For example, South Africa’s Biovac Institute expanded its mRNA vaccine production capacity in partnership with Pfizer, while Egypt’s VACSERA ramped up production of polio and meningitis vaccines for regional distribution. These efforts align with the African Union’s goal of producing 60% of the continent’s vaccine needs locally by 2040.

Digital Health and E-Pharmacy Platforms Enhancing Medicine Access

The proliferation of digital health solutions and e-pharmacy platforms presents a transformative opportunity for the Africa pharmaceutical market by improving medicine accessibility, streamlining supply chains, and enhancing patient engagement. With mobile penetration exceeding 80% in many African countries, digital tools are increasingly being used to connect patients with pharmacies, track prescriptions, and manage medication adherence.

Startups such as Nigeria’s LifeBank, Kenya’s MyDawa, and South Africa’s HelloDoctor have emerged as key players in this space, leveraging mobile apps and logistics networks to deliver medicines directly to consumers.

Moreover, digital health platforms are playing a crucial role in reducing stockouts and optimizing inventory management across supply chains. The African Union’s Digital Health Strategy for Africa emphasizes the integration of digital tools to strengthen pharmaceutical systems and improve health outcomes.

MARKET CHALLENGES

Reliance on Imported Active Pharmaceutical Ingredients (APIs)

The heavy dependence on imported active pharmaceutical ingredients (APIs), which undermines the sustainability and competitiveness of local drug manufacturing, is one of the most pressing challenges confronting the Africa pharmaceutical market. Despite growing interest in domestic pharmaceutical production, most African countries import over 90% of their APIs, primarily from China and India.

According to the United Nations Conference on Trade and Development (UNCTAD), in 2023, African pharmaceutical firms spent over USD 2 billion annually on API imports, exposing them to price volatility, supply chain disruptions, and geopolitical trade tensions. The reliance on external sources also delays production timelines and increases manufacturing costs, making locally produced medicines less competitive compared to imported generics.

Efforts to establish regional API hubs have been slow due to high capital requirements, limited technical expertise, and insufficient government incentives. While initiatives such as the African Continental Free Trade Area (AfCFTA) aim to promote intra-African trade in pharmaceutical inputs, progress remains uneven across member states.

Fragmented Distribution Networks and Poor Last-Mile Delivery

The fragmentation of distribution networks and the inefficiencies associated with last-mile delivery, particularly in rural and remote areas, is a persistent challenge in the Africa pharmaceutical market. Due to an underdeveloped logistics infrastructure, poor road conditions, and limited cold-chain storage capabilities, ensuring consistent medicine availability across all regions remains a formidable task.

According to the World Bank, in 2023, only 35% of rural populations in sub-Saharan Africa lived within two kilometers of an all-season road, severely limiting access to essential medicines. Moreover, the absence of centralized warehousing and real-time inventory tracking systems results in frequent stockouts and expired product waste.

Non-profit organizations and private sector actors have attempted to fill these gaps through drone deliveries and mobile pharmacies. For instance, Zipline, a medical drone company, expanded its operations to Rwanda and Ghana in 2023, delivering critical medicines to remote clinics in under an hour.

SEGMENTAL ANALYSIS

By Molecule Type Insights

The conventional drugs segment, primarily small molecule medicines, led the Africa pharmaceutical market led accounting for a substantial share of total revenue in 2024. Their widespread use in treating prevalent diseases such as malaria, tuberculosis, HIV/AIDS, and bacterial infections, which continue to affect millions across the continent is attributed to the dominance of conventional drugs segment.

According to the World Health Organization, in 2023, over 90% of antiretroviral treatments used in sub-Saharan Africa were based on small molecule formulations due to their stability, affordability, and ease of administration. Further, antibiotics and antimalarials—also small molecules—remain among the most frequently dispensed medications in both public and private health facilities.

The cost-effectiveness of generic small molecule drugs further strengthens their position. As per the African Union, generics accounted for nearly 85% of all prescriptions filled in 2023, with small molecule-based medicines forming the bulk of these prescriptions. These factors reinforce the entrenched leadership of conventional drugs in the Africa pharmaceutical market.

The biologics and biosimilars segment is the fastest-growing segment in the Africa pharmaceutical market and is projected to expand at a CAGR of 11.6% in the future. Increasing demand for advanced therapies targeting chronic conditions such as cancer, diabetes, and autoimmune disorders is fuelling the rapid ascent of biologics and biosimilars segment. The rising incidence of non-communicable diseases (NCDs), particularly in urban centers is another key driver of this segment.

Apart from these, international collaborations aimed at localizing production are accelerating market expansion. For example, South Africa’s Biovac Institute partnered with Pfizer in 2023 to produce mRNA vaccines, while Egypt’s VACSERA expanded its insulin manufacturing capabilities using imported biologic inputs.

Government support through regulatory reforms and investment incentives is also fostering growth. The African Medicines Agency is working to harmonize biosimilar approval processes, enhancing confidence among manufacturers and healthcare providers. These developments signal strong momentum for the biologics and biosimilars segment in the coming decade.

By Product Type Insights

The generics segment dominated the Africa pharmaceutical market in 2024. Economic constraints faced by both governments and consumers, making affordable medicines essential in a region where out-of-pocket healthcare expenditure remains high is largely the reason behind the overwhelming dominance of generics segment.

According to the World Bank, in 2023, nearly 60% of healthcare spending in sub-Saharan Africa was out-of-pocket, compelling patients and providers to prioritize cost-effective treatment options. Generics offer a viable alternative to branded medications, often at a fraction of the price, without compromising therapeutic efficacy.

Furthermore, regulatory bodies across the continent have been actively promoting the use of generics to improve medicine accessibility. As per the Kenyan Pharmacy and Poisons Board, in 2023, over 90% of prescriptions issued in public hospitals were for generic medicines, reflecting policy-driven adoption.

International donors and NGOs also favor generic procurement for large-scale disease management programs. As per the Global Fund, in 2023, over USD 1.2 billion worth of generic antiretrovirals and antimalarials were distributed across Africa under donor-funded initiatives. These patterns firmly establish generics as the cornerstone of the African pharmaceutical landscape.

The branded pharmaceuticals segment is experiencing robust growth, expanding at a CAGR of approximately 9.4% from 2023 to 2030. Increasing consumer awareness, rising disposable incomes, and a growing preference for trusted, quality-assured medications among urban populations is propelling the growth of branded pharmaceuticals segment.

As urbanization accelerates, particularly in Nigeria, Kenya, and Ghana, a more affluent middle class is emerging, willing to pay a premium for branded products perceived to be safer and more effective.

Pharmaceutical companies are responding by strengthening their brand presence through digital marketing, direct-to-consumer campaigns, and partnerships with private clinics and pharmacies. Multinational firms such as GlaxoSmithKline and Sanofi have intensified their branding strategies in African markets, leveraging social media and mobile platforms to reach younger demographics.

Moreover, improvements in regulatory enforcement are reducing the prevalence of counterfeit medicines, thereby boosting consumer trust in branded products.

By Drug Type Insights

The prescription drugs segment accounted for the majority of pharmaceutical sales in Africa in 2023. The dominance of this segment is largely due to the high burden of infectious diseases requiring physician-administered treatments and government-led public health interventions that rely heavily on prescription-based medication distribution.

Similarly, tuberculosis and malaria treatment protocols require diagnostic confirmation and clinician oversight before dispensing medicines.

Public health systems across the continent operate under strict guidelines that limit the sale of potent or controlled substances to prescription-only channels. In countries like Ethiopia and Tanzania, pharmacy regulations prohibit over-the-counter sales of antibiotics and antivirals, reinforcing the prescription drug segment's stronghold.

Besides, the limited availability of trained pharmacists and weak self-medication culture in many regions further consolidate the reliance on prescription-based pharmaceutical consumption.

The over-the-counter (OTC) medications segment is the fastest-growing segment in the Africa pharmaceutical market, registering a CAGR of approximately 10.2% from 2025 to 2033. This growth is fueled by increasing consumer health awareness, greater availability of OTC products in retail and online channels, and a shift toward self-care practices in urban areas.

Urbanization and digital literacy have empowered consumers to seek immediate relief for minor ailments without visiting a doctor.

The proliferation of community pharmacies, drug shops, and e-pharmacies has also facilitated easier access to OTC medicines.

Moreover, regulatory authorities are gradually expanding the list of approved OTC products to reduce pressure on healthcare systems. As per the South African Health Products Regulatory Authority, in 2023, several previously prescription-only medications were reclassified as OTC following safety assessments, signaling a broader trend toward consumer-driven healthcare solutions.

REGIONAL ANALYSIS

South Africa Pharmaceutical Market Insights

South Africa held the leading position in the Africa pharmaceutical market, accounting for 22.3% of total regional revenue in 2024. It is the most developed pharmaceutical market on the continent, characterized by a well-established regulatory framework, a robust manufacturing base, and significant investments in research and development.

The country is home to numerous multinational pharmaceutical firms, including Johnson & Johnson, Roche, and Aspen Pharmacare—the largest generic drug manufacturer in Africa.

Public health programs, particularly those focused on HIV/AIDS treatment, drive a substantial portion of pharmaceutical demand. As per the National Department of Health, in 2023, over 5 million people were receiving antiretroviral therapy under state-funded programs, significantly boosting medication consumption.

Nigeria Pharmaceutical Market Insights

Nigeria is a significant player in the Africa pharmaceutical market, primarily due to its vast population and high disease burden. With over 220 million people, Nigeria represents the single largest consumer base for medicines in sub-Saharan Africa.

Despite limited domestic production capacity, the country imports over USD 2 billion worth of pharmaceutical products annually. However, recent government policies aimed at revitalizing local manufacturing have spurred investments in drug formulation and packaging plants.

Challenges such as counterfeit medicines and fragmented supply chains persist, but the rise of digital pharmacies and improved regulatory enforcement is helping to stabilize the market.

Egypt Pharmaceutical Market Insights

Egypt is positioning itself as a strategic production and export center in North Africa. The country hosts a notable number of pharmaceutical companies, including domestic giants like EIPICO and international players such as Novartis and Pfizer.

Egypt’s favorable tax policies and investment incentives have attracted considerable foreign capital into the sector.

The government has also prioritized vaccine manufacturing, with institutions like VACSERA playing a critical role in producing polio, meningitis, and influenza vaccines for regional distribution.

With continued investment in biopharma and regulatory modernization, Egypt is poised to maintain its influence in both domestic and pan-African pharmaceutical trade.

Kenya Pharmaceutical Market Insights

Kenya is serving as a key distribution and logistics hub for East Africa. The country benefits from a relatively stable business environment, strong port infrastructure, and proximity to landlocked nations such as Uganda, South Sudan, and Rwanda.

Local production is gradually expanding, supported by government initiatives such as the Affordable Medicines Program and the establishment of the Kenya Medical Supplies Authority (KEMSA) to streamline procurement.

With growing interest in digital health platforms and stronger regulatory oversight, Kenya continues

Morocco Pharmaceutical Market Insights

Morocco is functioning as a key manufacturing and export hub in North Africa. The country is home to over 150 pharmaceutical companies, including global players like Sanofi and Servier, as well as prominent domestic firms such as Sothema and Genecor.

According to the Moroccan Ministry of Industry, in 2023, the pharmaceutical sector generated over MAD 35 billion (~USD 3.4 billion) in revenue, with exports to over 30 African and European countries. Morocco’s strategic location, skilled workforce, and participation in trade agreements such as the African Continental Free Trade Area (AfCFTA) enhance its competitive edge.

The government has actively supported the sector through industrial clusters like the Casablanca Special Economic Zone and the implementation of the "Made in Morocco" initiative, which encourages local sourcing and production. These factors solidify Morocco’s role as a leading pharmaceutical player in the region.

KEY MARKET PLAYERS AND COMPETITIVE LANDSCAPE

Some of the key players operating in the Africa pharmaceutical market include Aspen Pharmacare Holdings Limited, Adcock Ingram Holdings Ltd, Cipla Medpro South Africa (Pty) Limited, GlaxoSmithKline plc, Pfizer Inc., Novartis AG, Sanofi S.A., Roche Holding AG, Johnson & Johnson, Merck & Co., Inc., Bayer AG, Abbott Laboratories, Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Valeant Pharmaceuticals International, Inc., Endo International plc, and Aurobindo Pharma Limited.

The competition in the Africa pharmaceutical market is marked by a dynamic mix of multinational corporations, regional manufacturers, and a vast informal sector comprising small-scale producers and unregulated vendors. While global pharmaceutical giants dominate high-value segments such as vaccines and biologics, regional players are gaining ground through cost-effective generic drug production and improved distribution strategies. Local manufacturers face intense pressure from imported medicines, particularly from India and China, which offer lower prices and higher volumes. However, growing emphasis on self-reliance and regional trade agreements is encouraging domestic investment and fostering innovation among indigenous firms. Moreover, regulatory reforms and the expansion of digital health platforms are reshaping how medicines are accessed and distributed, further intensifying market dynamics. The interplay between affordability, quality assurance, and accessibility continues to define competitive positioning, with companies striving to balance profitability with public health impact. As demand for essential medicines rises alongside chronic disease prevalence, the race to provide affordable, reliable, and locally adapted pharmaceutical solutions has become more pronounced than ever.

Top Players in the Africa Pharmaceutical Market

Aspen Pharmacare (South Africa)

Aspen Pharmacare is the largest pharmaceutical manufacturer headquartered in Africa, with a strong presence across multiple continents. The company specializes in the production of generic medicines, hospital products, and active pharmaceutical ingredients. Its strategic partnerships and investments in advanced manufacturing facilities have enabled it to serve both domestic and international markets effectively.

Sanofi (France, with major operations in North and West Africa)

Sanofi maintains a significant footprint in the Africa pharmaceutical market through its vaccine distribution, diabetes care, and consumer healthcare divisions. In several African countries, Sanofi collaborates with governments and health organizations to improve access to essential medicines, particularly for diseases like malaria and meningitis.

GlaxoSmithKline (GSK) (United Kingdom, with extensive regional engagement)

GSK plays a crucial role in the Africa pharmaceutical market by supplying vaccines, antiretrovirals, and over-the-counter medications. Through public-private partnerships and localized distribution networks, GSK supports disease prevention and treatment programs, especially in rural and underserved areas across the continent.

Top Strategies Used by Key Market Participants

One major strategy employed by key players in the Africa pharmaceutical market is expanding local manufacturing capabilities. By setting up or upgrading production facilities within African countries, companies reduce dependency on imports, cut costs, and align with regulatory requirements that favor local sourcing.

Another widely adopted approach is forming strategic alliances with governments and global health organizations. These collaborations help pharmaceutical firms gain access to large-scale procurement contracts, streamline distribution networks, and participate in disease eradication initiatives, thereby enhancing brand credibility and market reach.

A third critical strategy involves leveraging digital technologies and e-health platforms to improve medicine accessibility and patient engagement. Companies are increasingly investing in mobile-based pharmacy services, telemedicine integrations, and digital supply chain solutions to overcome infrastructure challenges and deliver more efficient healthcare outcomes across the region.

RECENT MARKET DEVELOPMENTS

• In February 2023, Aspen Pharmacare expanded its manufacturing facility in Durban, South Africa, to increase production capacity for injectable medicines, reinforcing its leadership in the African generics market.
• In July 2023, Sanofi partnered with the African Union to support vaccine development and distribution across sub-Saharan Africa, strengthening its role in regional immunization programs.
• In November 2023, GlaxoSmithKline launched a new community health initiative in Nigeria aimed at improving access to over-the-counter medicines and maternal health products in rural areas.
• In March 2024, Egypt’s VACSERA signed a technology transfer agreement with a European biopharma firm to enhance its vaccine production capabilities, positioning itself as a continental supplier.
• In June 2024, a consortium of East African pharmaceutical firms established a shared logistics network to streamline medicine delivery across Kenya, Uganda, and Tanzania, addressing long-standing supply chain inefficiencies.

MARKET SEGMENTATION

This research report on the Africa pharmaceutical market is segmented and sub-segmented into the following categories.

By Molecule Type

• Conventional Drugs
• Biologics & Biosimilars
  • Monoclonal Antibodies
  • Vaccines
  • Cell & Gene Therapy
  • Others

By Product

• Generic
• Branded

By Disease

• Cardiovascular diseases
• Cancer
• Diabetes
• Infectious diseases
• Neurological disorders
• Respiratory diseases
• Autoimmune diseases
• Mental health disorders
• Gastrointestinal disorders
• Women’s health diseases
• Genetic and rare genetic diseases
• Dermatological conditions
• Obesity
• Renal diseases
• Liver conditions
• Hematological disorders
• Eye conditions
• Infertility conditions
• Endocrine disorders
• Allergies
• Others

By Type

• Prescription
• OTC

By Route of Administration

• Oral
  • Tablets
  • Capsules
  • Suspensions
  • Other
• Topical
• Parenteral
  • Intravenous
  • Intramuscular
• Inhalations
• Other

By Age Group

• Children & Adolescents
• Adults
• Geriatric

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

By Country

• South Africa
• Nigeria
• Rest of Africa